Loading…

Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas

Background Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aim...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2023-12, Vol.30 (13), p.8621-8630
Main Authors: Miyata, Yoichi, Yonamine, Naoto, Fujinuma, Ibuki, Tsunenari, Takazumi, Takihata, Yasuhiro, Hakoda, Hiroyuki, Nakazawa, Akiko, Iwasaki, Toshimitsu, Einama, Takahiro, Togashi, Junichi, Tsujimoto, Hironori, Ueno, Hideki, Beck, Yoshifumi, Kishi, Yoji
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13
cites cdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13
container_end_page 8630
container_issue 13
container_start_page 8621
container_title Annals of surgical oncology
container_volume 30
creator Miyata, Yoichi
Yonamine, Naoto
Fujinuma, Ibuki
Tsunenari, Takazumi
Takihata, Yasuhiro
Hakoda, Hiroyuki
Nakazawa, Akiko
Iwasaki, Toshimitsu
Einama, Takahiro
Togashi, Junichi
Tsujimoto, Hironori
Ueno, Hideki
Beck, Yoshifumi
Kishi, Yoji
description Background Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs. Methods Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS small and TS large groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum P value approach for the risk of R1 resection. Results TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS large than TS small group, in both R- ( n = 35, 37% versus n = 294, 19%; P = 0.011) and BR-PDAC ( n = 89, 37% versus n = 27, 15%; P = 0.030). Overall survival was significantly better in the TS small than TS large group in R-PDAC (38.2 versus 12.1 months; P < 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months; P = 0.363). Multivariate analysis revealed TS > 35 mm as an independent predictor of worse survival in patients with R-PDAC. Conclusion Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.
doi_str_mv 10.1245/s10434-023-14219-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2860404420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2860404420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</originalsourceid><addsrcrecordid>eNp9kV1PFTEQhhsjETj6B7wwTbzhZqHTj_24RFQgIYEgXjdtdw5Zstse210j_HoHD6LxwqRJm5ln3pnOy9hbEIcgtTkqILTSlZCqAi2hq9QLtgeGQrpu4SW9Rd1WnazNLtsv5U4IaJQwr9iuamrTykbtsR_n08aFmac1v8qYNpjdPHxHfrNMKfMvwwPyFCmVbmMqQ3nkrrFgmJ0fkbvY8w8p95jHIeLfmSsXQ0bSCvzjQrGRH_cYU3A5DDFNrrxmO2s3FnzzdK_Y18-fbk7OqovL0_OT44sqqMbMlaTxaVjw2qyD9B22QEeh8C2CMaA8_bVvVCcVLaPulYLQgQ_et01TI6gVO9jqbnL6tmCZ7TSUgOPoIqalWNnWQgutpSD0_T_oXVpypOmIamswUtHOVkxuqZBTKRnXdpOHyeV7C8I--mK3vljyxf7yxSoqevckvfgJ--eS30YQoLZAoVS8xfyn939kfwKlF5fV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886152327</pqid></control><display><type>article</type><title>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</title><source>Springer Nature</source><creator>Miyata, Yoichi ; Yonamine, Naoto ; Fujinuma, Ibuki ; Tsunenari, Takazumi ; Takihata, Yasuhiro ; Hakoda, Hiroyuki ; Nakazawa, Akiko ; Iwasaki, Toshimitsu ; Einama, Takahiro ; Togashi, Junichi ; Tsujimoto, Hironori ; Ueno, Hideki ; Beck, Yoshifumi ; Kishi, Yoji</creator><creatorcontrib>Miyata, Yoichi ; Yonamine, Naoto ; Fujinuma, Ibuki ; Tsunenari, Takazumi ; Takihata, Yasuhiro ; Hakoda, Hiroyuki ; Nakazawa, Akiko ; Iwasaki, Toshimitsu ; Einama, Takahiro ; Togashi, Junichi ; Tsujimoto, Hironori ; Ueno, Hideki ; Beck, Yoshifumi ; Kishi, Yoji</creatorcontrib><description>Background Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs. Methods Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS small and TS large groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum P value approach for the risk of R1 resection. Results TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS large than TS small group, in both R- ( n = 35, 37% versus n = 294, 19%; P = 0.011) and BR-PDAC ( n = 89, 37% versus n = 27, 15%; P = 0.030). Overall survival was significantly better in the TS small than TS large group in R-PDAC (38.2 versus 12.1 months; P &lt; 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months; P = 0.363). Multivariate analysis revealed TS &gt; 35 mm as an independent predictor of worse survival in patients with R-PDAC. Conclusion Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-023-14219-3</identifier><identifier>PMID: 37658273</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adenocarcinoma ; Carcinoma, Pancreatic Ductal - surgery ; Humans ; Medical prognosis ; Medicine ; Medicine &amp; Public Health ; Multivariate analysis ; Oncology ; Pancreas ; Pancreatectomy - adverse effects ; Pancreatic cancer ; Pancreatic Neoplasms ; Pancreatic Neoplasms - surgery ; Pancreatic Tumors ; Prognosis ; Retrospective Studies ; Surgery ; Surgical Oncology ; Survival ; Tumors</subject><ispartof>Annals of surgical oncology, 2023-12, Vol.30 (13), p.8621-8630</ispartof><rights>Society of Surgical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. Society of Surgical Oncology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</citedby><cites>FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</cites><orcidid>0000-0002-5201-4477</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37658273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyata, Yoichi</creatorcontrib><creatorcontrib>Yonamine, Naoto</creatorcontrib><creatorcontrib>Fujinuma, Ibuki</creatorcontrib><creatorcontrib>Tsunenari, Takazumi</creatorcontrib><creatorcontrib>Takihata, Yasuhiro</creatorcontrib><creatorcontrib>Hakoda, Hiroyuki</creatorcontrib><creatorcontrib>Nakazawa, Akiko</creatorcontrib><creatorcontrib>Iwasaki, Toshimitsu</creatorcontrib><creatorcontrib>Einama, Takahiro</creatorcontrib><creatorcontrib>Togashi, Junichi</creatorcontrib><creatorcontrib>Tsujimoto, Hironori</creatorcontrib><creatorcontrib>Ueno, Hideki</creatorcontrib><creatorcontrib>Beck, Yoshifumi</creatorcontrib><creatorcontrib>Kishi, Yoji</creatorcontrib><title>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs. Methods Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS small and TS large groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum P value approach for the risk of R1 resection. Results TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS large than TS small group, in both R- ( n = 35, 37% versus n = 294, 19%; P = 0.011) and BR-PDAC ( n = 89, 37% versus n = 27, 15%; P = 0.030). Overall survival was significantly better in the TS small than TS large group in R-PDAC (38.2 versus 12.1 months; P &lt; 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months; P = 0.363). Multivariate analysis revealed TS &gt; 35 mm as an independent predictor of worse survival in patients with R-PDAC. Conclusion Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.</description><subject>Adenocarcinoma</subject><subject>Carcinoma, Pancreatic Ductal - surgery</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Pancreas</subject><subject>Pancreatectomy - adverse effects</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>Pancreatic Tumors</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Tumors</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kV1PFTEQhhsjETj6B7wwTbzhZqHTj_24RFQgIYEgXjdtdw5Zstse210j_HoHD6LxwqRJm5ln3pnOy9hbEIcgtTkqILTSlZCqAi2hq9QLtgeGQrpu4SW9Rd1WnazNLtsv5U4IaJQwr9iuamrTykbtsR_n08aFmac1v8qYNpjdPHxHfrNMKfMvwwPyFCmVbmMqQ3nkrrFgmJ0fkbvY8w8p95jHIeLfmSsXQ0bSCvzjQrGRH_cYU3A5DDFNrrxmO2s3FnzzdK_Y18-fbk7OqovL0_OT44sqqMbMlaTxaVjw2qyD9B22QEeh8C2CMaA8_bVvVCcVLaPulYLQgQ_et01TI6gVO9jqbnL6tmCZ7TSUgOPoIqalWNnWQgutpSD0_T_oXVpypOmIamswUtHOVkxuqZBTKRnXdpOHyeV7C8I--mK3vljyxf7yxSoqevckvfgJ--eS30YQoLZAoVS8xfyn939kfwKlF5fV</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Miyata, Yoichi</creator><creator>Yonamine, Naoto</creator><creator>Fujinuma, Ibuki</creator><creator>Tsunenari, Takazumi</creator><creator>Takihata, Yasuhiro</creator><creator>Hakoda, Hiroyuki</creator><creator>Nakazawa, Akiko</creator><creator>Iwasaki, Toshimitsu</creator><creator>Einama, Takahiro</creator><creator>Togashi, Junichi</creator><creator>Tsujimoto, Hironori</creator><creator>Ueno, Hideki</creator><creator>Beck, Yoshifumi</creator><creator>Kishi, Yoji</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5201-4477</orcidid></search><sort><creationdate>20231201</creationdate><title>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</title><author>Miyata, Yoichi ; Yonamine, Naoto ; Fujinuma, Ibuki ; Tsunenari, Takazumi ; Takihata, Yasuhiro ; Hakoda, Hiroyuki ; Nakazawa, Akiko ; Iwasaki, Toshimitsu ; Einama, Takahiro ; Togashi, Junichi ; Tsujimoto, Hironori ; Ueno, Hideki ; Beck, Yoshifumi ; Kishi, Yoji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>Carcinoma, Pancreatic Ductal - surgery</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Pancreas</topic><topic>Pancreatectomy - adverse effects</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>Pancreatic Tumors</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyata, Yoichi</creatorcontrib><creatorcontrib>Yonamine, Naoto</creatorcontrib><creatorcontrib>Fujinuma, Ibuki</creatorcontrib><creatorcontrib>Tsunenari, Takazumi</creatorcontrib><creatorcontrib>Takihata, Yasuhiro</creatorcontrib><creatorcontrib>Hakoda, Hiroyuki</creatorcontrib><creatorcontrib>Nakazawa, Akiko</creatorcontrib><creatorcontrib>Iwasaki, Toshimitsu</creatorcontrib><creatorcontrib>Einama, Takahiro</creatorcontrib><creatorcontrib>Togashi, Junichi</creatorcontrib><creatorcontrib>Tsujimoto, Hironori</creatorcontrib><creatorcontrib>Ueno, Hideki</creatorcontrib><creatorcontrib>Beck, Yoshifumi</creatorcontrib><creatorcontrib>Kishi, Yoji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyata, Yoichi</au><au>Yonamine, Naoto</au><au>Fujinuma, Ibuki</au><au>Tsunenari, Takazumi</au><au>Takihata, Yasuhiro</au><au>Hakoda, Hiroyuki</au><au>Nakazawa, Akiko</au><au>Iwasaki, Toshimitsu</au><au>Einama, Takahiro</au><au>Togashi, Junichi</au><au>Tsujimoto, Hironori</au><au>Ueno, Hideki</au><au>Beck, Yoshifumi</au><au>Kishi, Yoji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>30</volume><issue>13</issue><spage>8621</spage><epage>8630</epage><pages>8621-8630</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs. Methods Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS small and TS large groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum P value approach for the risk of R1 resection. Results TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS large than TS small group, in both R- ( n = 35, 37% versus n = 294, 19%; P = 0.011) and BR-PDAC ( n = 89, 37% versus n = 27, 15%; P = 0.030). Overall survival was significantly better in the TS small than TS large group in R-PDAC (38.2 versus 12.1 months; P &lt; 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months; P = 0.363). Multivariate analysis revealed TS &gt; 35 mm as an independent predictor of worse survival in patients with R-PDAC. Conclusion Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>37658273</pmid><doi>10.1245/s10434-023-14219-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5201-4477</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1068-9265
ispartof Annals of surgical oncology, 2023-12, Vol.30 (13), p.8621-8630
issn 1068-9265
1534-4681
language eng
recordid cdi_proquest_miscellaneous_2860404420
source Springer Nature
subjects Adenocarcinoma
Carcinoma, Pancreatic Ductal - surgery
Humans
Medical prognosis
Medicine
Medicine & Public Health
Multivariate analysis
Oncology
Pancreas
Pancreatectomy - adverse effects
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - surgery
Pancreatic Tumors
Prognosis
Retrospective Studies
Surgery
Surgical Oncology
Survival
Tumors
title Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A01%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Preoperative%20Tumor%20Size%20on%20Prognosis%20of%20Resectable%20and%20Borderline%20Resectable%20Pancreatic%20Ductal%20Adenocarcinomas&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Miyata,%20Yoichi&rft.date=2023-12-01&rft.volume=30&rft.issue=13&rft.spage=8621&rft.epage=8630&rft.pages=8621-8630&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-023-14219-3&rft_dat=%3Cproquest_cross%3E2860404420%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2886152327&rft_id=info:pmid/37658273&rfr_iscdi=true